Levothyroxine NDAs May Be Refused Filing After First Product Approval - FDA
Levothyroxine NDAs may be refused filing following approval of the first levothyroxine product, FDA said in a draft guidance issued August 18.
Levothyroxine NDAs may be refused filing following approval of the first levothyroxine product, FDA said in a draft guidance issued August 18.